Shares of Aurora Cannabis Inc. dropped almost -10% during after-hours trading Wednesday, after the company reported net revenue that fell short of its previously lowered guidance.
The Canadian cannabis company’s fiscal fourth-quarter consolidated net revenue increased +52% from the previous quarter to C$98.9 million – lower than the C$100 million to C$107 million guidance the company had provided offered last month.
Aurora’s adjusted EBITDA loss was -C$11.7 million.
In a separate filing, Aurora said that its net loss attributable to common shareholders was less than -C$200,000, and less than a penny a share, with the rest of the losses attributed to two subsidiaries’ non-controlling interests.
Aurora mentioned that it is working closely with all regulatory and channel partners to streamline distribution, amidst challenges facing the Canadian consumer channel at the retail level in its key markets.
Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ACB entered a downward trend on October 08, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on October 15, 2024. You may want to consider a long position or call options on ACB as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ACB just turned positive on October 14, 2024. Looking at past instances where ACB's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .
ACB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ACB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.630) is normal, around the industry mean (56.029). P/E Ratio (0.000) is within average values for comparable stocks, (89.935). ACB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.890). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (1.538) is also within normal values, averaging (18.706).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a licensed producer of medical marijuana in Canada
Industry PharmaceuticalsOther